ASS1 and glioblastoma: While the impact of ADI on glioblastoma (GBM) cells does not appear to be compromised by tumor stem cells leading to drug resistance (Linke et al., 2023), other tumor types have exhibited resistance phenomena and withdrawal reflexes due to the re-expression of AS or ASS1.